<DOC>
	<DOCNO>NCT00458900</DOCNO>
	<brief_summary>In Intensive Care ( IC ) -unit moxifloxacin treatment often start intravenous administration . As moxifloxacin know high oral bioavailability healthy volunteer , patient switch oral enteral therapy soon possible . However , data plasma level moxifloxacin switch-therapy IC-patients available . Therefore , study aim evaluate moxifloxacin-plasma level inter-individual variability IV enteral switch therapy IC-patients .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Moxifloxacin IV Enteral Switch Therapy Intensive Care Patients</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>IC patient treat 400 mg moxifloxacin IV ( day ) switch enteral administration 400 mg moxifloxacin . IV steady state Hemodynamic stability Normal enteral feeding without prokinetics Presence arterial line Informed consent â‰¥ 18 jaar Dialysis patient Creatinine clearance &lt; 30 ml/min Transaminase level &gt; 5x upper limit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>